SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses of $15.09M in Q1 FY2026
Q1 FY2026 operating expenses was $15.09M.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 40.84M USD
- Year-over-year change
- —
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 40.84M | — |
Operating Expenses vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $5.15B USD | +23.4% | +2.5% | 47.1% | |
| LTM Jun 2026 | $2.66B USD | -1.5% | +8.5% | 50.1% | |
| LTM Jun 2026 | $565.37M USD | +32.3% | +17.5% | 92.3% | |
| LTM Mar 2026 | $344.84M USD | +33.6% | +35.9% | 662.7% | |
| LTM Mar 2026 | $287.65M USD | +34.6% | +27.1% | 3777.4% | |
| LTM Apr 2026 | $226.94M USD | -17.3% | +8.3% | 78.2% | |
| LTM Mar 2026 | $153.52M USD | +7.0% | +21.3% | 120.4% | |
| LTM Mar 2026 | $104.2M USD | -10.6% | -10.1% | 131.0% | |
| LTM Mar 2026 | CHF 69.81M CHF | -10.3% | +34.7% | 13851.6% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $40.84M USD | — | — | — |
| Peer median (excluding SGP) | — | +7.0% | +17.5% | 120.4% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 612K |
| Gross Profit | (612K) |
| Gross Margin | — |
| Research & Development | 28.64M |
| Selling, General & Admin | 12.2M |
| Operating Expenses | 40.84M |
| Depreciation & Amortization | 612K |
| EBITDA | (39.26M) |
| EBITDA Margin | — |
| Operating Income | (41.45M) |
| Operating Margin | — |
| Interest Income | 3.11M |
| Interest Expense | 0 |
| Other Income / Expenses | 1.58M |
| Income Before Tax | (39.87M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (39.87M) |
| Net Margin | — |
| EPS (Basic) | (1.19) |
| EPS (Diluted) | (1.19) |
| Weighted Avg Shares | 33.43M |
| Weighted Avg Shares (Diluted) | 33.43M |
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.